Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90002 in advanced solid and hematologic cancers
NCT02367196Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2015
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of CC-90002 in solid tumor, multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Dose-Limiting Toxicity up to 18 months, Non-Tolerated Dose up to 24 months and 1 more. Started Mar 2015; status: completed.
02
Drugs
CC-90002
03
Conditions
solid tumormultiple myeloma (MM)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT02367196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367196.